Asia Pacific Cancer Drugs Market Size and Forecast (2021 - 2031)
The Asia Pacific Cancer Drugs Market is projected to grow significantly, reaching an estimated US$ 99,289.8 million by 2031, up from US$ 38,552.1 million in 2024. This growth represents a compound annual growth rate (CAGR) of 14.5% from 2025 to 2031, driven by various factors including an aging population, lifestyle changes, and increased healthcare spending.
Executive Summary and Market Analysis
The cancer drugs market in the Asia Pacific region is divided into several key countries: China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific. The incidence of cancer is rising sharply in these nations, attributed to demographic shifts such as a rapidly aging population, longer life expectancy, and lifestyle factors including poor diet, smoking, and insufficient physical activity. In 2023, the region accounted for a substantial share of global cancer cases, with significant numbers of new diagnoses of breast, lung, colorectal, and stomach cancers.
Governments across the Asia Pacific are responding to this crisis by increasing healthcare budgets, providing incentives for biotechnology development, approving new cancer treatments, and integrating advanced therapies into national health insurance programs. Countries like China and India are particularly attractive for global investment due to lower research and development costs and large populations ready for clinical trials. Additionally, partnerships are emerging, such as Chinese firms licensing PD1/PDL1 drugs to Western companies, showcasing the region's competitive edge in the biotech sector.
Japan, South Korea, and Australia are noted for their robust regulatory frameworks that support precision oncology. South Korea is expediting access to CAR-T therapies and novel biologics, while Australia is enhancing its national screening programs and clinical infrastructure. The expansion of healthcare facilities and the availability of advanced treatment options are crucial drivers of market growth in this region. Furthermore, the rise of biosimilars is making cancer treatments more affordable, thereby increasing accessibility for patients across the Asia Pacific.
Strategic Insights
Market Segmentation Analysis
The Asia Pacific Cancer Drugs Market can be segmented by therapy types, indications, and distribution channels:
Governments in the Asia Pacific recognize the critical need for a robust cancer treatment landscape and are implementing policies to enhance access to effective therapies. Increased funding for cancer research and development from both governmental and private sectors has led to the emergence of innovative drugs and therapies. For instance, the Indian government allocated approximately US$ 12 billion in its 2025-2026 budget to the Ministry of Health and Family Welfare, which includes initiatives to establish 200 Day Care Cancer Centres in district hospitals by 2025-2026 as part of the National Programme for Prevention and Control of Cancer (NPCDCS).
These initiatives aim to make cancer treatments more accessible through favorable reimbursement policies and other healthcare initiatives, ensuring that patients receive adequate coverage for cancer therapeutics. With enhanced funding and resources, healthcare providers can offer a broader range of treatment options, improving patient outcomes and maintaining competitiveness in the market. The increased support from governments and private organizations for the development and utilization of cancer therapeutics fosters innovation, creating significant growth opportunities in the cancer drugs market.
Country Insights
The Asia Pacific Cancer Drugs Market is further analyzed by country, with China holding the largest market share in 2024. According to the World Health Organization (WHO), approximately 4.5 million new cancer cases and 3 million cancer-related deaths were reported in China in 2020. The WHO estimates that every minute, around seven individuals are diagnosed with cancer, and four succumb to the disease. The most prevalent cancers in China include lung, stomach, breast, thyroid, and leukemia.
Factors such as an aging population, lifestyle changes, urbanization, and high smoking rates are contributing to the increasing cancer incidence and chronic disease burden. A study published in 2020 indicated that the proportion of individuals aged 60 and above in China is expected to rise from 12.4% (168 million) in 2010 to 28% (402 million) by 2040, highlighting the growing vulnerability of older adults to cancer.
Company Profiles
Key players in the Asia Pacific Cancer Drugs Market include F. Hoffmann-La Roche Ltd, Pfizer Inc, Novartis AG, Bristol-Myers Squibb Co, Johnson & Johnson, AstraZeneca Plc, Astellas Pharma Inc, AbbVie Inc, Merck KGaA, and Eli Lilly and Co. These companies are pursuing various strategies such as market expansion, product innovation, and mergers and acquisitions to enhance their offerings and increase market share.
Executive Summary and Market Analysis
The cancer drugs market in the Asia Pacific region is divided into several key countries: China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific. The incidence of cancer is rising sharply in these nations, attributed to demographic shifts such as a rapidly aging population, longer life expectancy, and lifestyle factors including poor diet, smoking, and insufficient physical activity. In 2023, the region accounted for a substantial share of global cancer cases, with significant numbers of new diagnoses of breast, lung, colorectal, and stomach cancers.
Governments across the Asia Pacific are responding to this crisis by increasing healthcare budgets, providing incentives for biotechnology development, approving new cancer treatments, and integrating advanced therapies into national health insurance programs. Countries like China and India are particularly attractive for global investment due to lower research and development costs and large populations ready for clinical trials. Additionally, partnerships are emerging, such as Chinese firms licensing PD1/PDL1 drugs to Western companies, showcasing the region's competitive edge in the biotech sector.
Japan, South Korea, and Australia are noted for their robust regulatory frameworks that support precision oncology. South Korea is expediting access to CAR-T therapies and novel biologics, while Australia is enhancing its national screening programs and clinical infrastructure. The expansion of healthcare facilities and the availability of advanced treatment options are crucial drivers of market growth in this region. Furthermore, the rise of biosimilars is making cancer treatments more affordable, thereby increasing accessibility for patients across the Asia Pacific.
Strategic Insights
Market Segmentation Analysis
The Asia Pacific Cancer Drugs Market can be segmented by therapy types, indications, and distribution channels:
- By Therapy Types: The market is categorized into Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy, and Other Therapy Types. Targeted Therapy is expected to lead the market in 2024.
- By Indications: The market is divided into Blood Cancer, Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Stomach Cancer, Cervical Cancer, Liver and Intrahepatic Bile Ducts Cancer, Thyroid Cancer, and Other Indications. The Other Indications segment is anticipated to dominate in 2024.
- By Distribution Channel: The market is segmented into Hospital Pharmacies, Retail Pharmacies, and Online Stores, with Hospital Pharmacies expected to hold the largest share in 2024.
Governments in the Asia Pacific recognize the critical need for a robust cancer treatment landscape and are implementing policies to enhance access to effective therapies. Increased funding for cancer research and development from both governmental and private sectors has led to the emergence of innovative drugs and therapies. For instance, the Indian government allocated approximately US$ 12 billion in its 2025-2026 budget to the Ministry of Health and Family Welfare, which includes initiatives to establish 200 Day Care Cancer Centres in district hospitals by 2025-2026 as part of the National Programme for Prevention and Control of Cancer (NPCDCS).
These initiatives aim to make cancer treatments more accessible through favorable reimbursement policies and other healthcare initiatives, ensuring that patients receive adequate coverage for cancer therapeutics. With enhanced funding and resources, healthcare providers can offer a broader range of treatment options, improving patient outcomes and maintaining competitiveness in the market. The increased support from governments and private organizations for the development and utilization of cancer therapeutics fosters innovation, creating significant growth opportunities in the cancer drugs market.
Country Insights
The Asia Pacific Cancer Drugs Market is further analyzed by country, with China holding the largest market share in 2024. According to the World Health Organization (WHO), approximately 4.5 million new cancer cases and 3 million cancer-related deaths were reported in China in 2020. The WHO estimates that every minute, around seven individuals are diagnosed with cancer, and four succumb to the disease. The most prevalent cancers in China include lung, stomach, breast, thyroid, and leukemia.
Factors such as an aging population, lifestyle changes, urbanization, and high smoking rates are contributing to the increasing cancer incidence and chronic disease burden. A study published in 2020 indicated that the proportion of individuals aged 60 and above in China is expected to rise from 12.4% (168 million) in 2010 to 28% (402 million) by 2040, highlighting the growing vulnerability of older adults to cancer.
Company Profiles
Key players in the Asia Pacific Cancer Drugs Market include F. Hoffmann-La Roche Ltd, Pfizer Inc, Novartis AG, Bristol-Myers Squibb Co, Johnson & Johnson, AstraZeneca Plc, Astellas Pharma Inc, AbbVie Inc, Merck KGaA, and Eli Lilly and Co. These companies are pursuing various strategies such as market expansion, product innovation, and mergers and acquisitions to enhance their offerings and increase market share.
1. INTRODUCTION
1.1 Report Guidance
1.2 Market Segmentation
2. EXECUTIVE SUMMARY
2.1 Key Insights
2.2 Market Attractiveness
3. RESEARCH METHODOLOGY
3.1 Secondary Research
3.2 Primary Research
3.2.1 Hypothesis formulation:
3.2.2 Macroeconomic factor analysis:
3.2.3 Developing base number:
3.2.4 Data Triangulation:
3.2.5 Country-level data:
4. CANCER DRUGS MARKET LANDSCAPE
4.1 Market Overview
4.2 PEST Analysis
4.3 Ecosystem Analysis
4.4 List of Vendors in the Value Chain
5. ASIA PACIFIC CANCER DRUGS MARKET – KEY MARKET DYNAMICS
5.1 Market Drivers
5.2 Market Restraints
5.3 Market Opportunities
5.4 Future Trends
5.5 Impact of Drivers and Restraints:
6. CANCER DRUGS MARKET - ASIA PACIFIC MARKET ANALYSIS
6.1 Asia Pacific Cancer Drugs Market Revenue (US$ Million), 2024 – 2031
6.2 Asia Pacific Cancer Drugs Market Forecast and Analysis
7. ASIA PACIFIC CANCER DRUGS MARKET REVENUE ANALYSIS – BY THERAPY TYPES
7.1 Chemotherapy
7.1.1 Overview
7.1.2 Chemotherapy: Asia Pacific Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
7.2 Targeted Therapy
7.2.1 Overview
7.2.2 Targeted Therapy: Asia Pacific Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
7.3 Immunotherapy
7.3.1 Overview
7.3.2 Immunotherapy: Asia Pacific Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
7.4 Hormonal Therapy
7.4.1 Overview
7.4.2 Hormonal Therapy: Asia Pacific Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
7.5 Other Therapy Types
7.5.1 Overview
7.5.2 Other Therapy Types: Asia Pacific Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
8. ASIA PACIFIC CANCER DRUGS MARKET REVENUE ANALYSIS – BY INDICATIONS
8.1 Blood Cancer
8.1.1 Overview
8.1.2 Blood Cancer: Asia Pacific Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
8.2 Lung Cancer
8.2.1 Overview
8.2.2 Lung Cancer: Asia Pacific Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
8.3 Breast Cancer
8.3.1 Overview
8.3.2 Breast Cancer: Asia Pacific Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
8.4 Colorectal Cancer
8.4.1 Overview
8.4.2 Colorectal Cancer: Asia Pacific Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
8.5 Prostate Cancer
8.5.1 Overview
8.5.2 Prostate Cancer: Asia Pacific Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
8.6 Stomach Cancer
8.6.1 Overview
8.6.2 Stomach Cancer: Asia Pacific Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
8.7 Cervical Cancer
8.7.1 Overview
8.7.2 Cervical Cancer: Asia Pacific Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
8.8 Liver and Intrahepatic Bile Ducts Cancer
8.8.1 Overview
8.8.2 Liver and Intrahepatic Bile Ducts Cancer: Asia Pacific Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
8.9 Thyroid Cancer
8.9.1 Overview
8.9.2 Thyroid Cancer: Asia Pacific Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
8.10 Other Indications
8.10.1 Overview
8.10.2 Other Indications: Asia Pacific Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
9. ASIA PACIFIC CANCER DRUGS MARKET REVENUE ANALYSIS – BY DISTRIBUTION CHANNEL
9.1 Hospital Pharmacies
9.1.1 Overview
9.1.2 Hospital Pharmacies: Asia Pacific Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
9.2 Retail Pharmacies
9.2.1 Overview
9.2.2 Retail Pharmacies: Asia Pacific Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
9.3 Online Stores
9.3.1 Overview
9.3.2 Online Stores: Asia Pacific Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
10. ASIA PACIFIC CANCER DRUGS MARKET – COUNTRY ANALYSIS
10.1 Asia Pacific
10.1.1 Asia Pacific Cancer Drugs Market Revenue and Forecast and Analysis – by Country
10.1.1.1 Asia Pacific Cancer Drugs Market Revenue and Forecast and Analysis – by Country
10.1.2.2 China: Asia Pacific Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
10.1.2.2.1 China: Asia Pacific Cancer Drugs Market Share – by Therapy Types
10.1.2.2.2 China: Asia Pacific Cancer Drugs Market Share – by Indications
10.1.2.2.3 China: Asia Pacific Cancer Drugs Market Share – by Distribution Channel
10.2.3.3 Japan: Asia Pacific Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
10.2.3.3.1 Japan: Asia Pacific Cancer Drugs Market Share – by Therapy Types
10.2.3.3.2 Japan: Asia Pacific Cancer Drugs Market Share – by Indications
10.2.3.3.3 Japan: Asia Pacific Cancer Drugs Market Share – by Distribution Channel
10.3.4.4 India: Asia Pacific Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
10.3.4.4.1 India: Asia Pacific Cancer Drugs Market Share – by Therapy Types
10.3.4.4.2 India: Asia Pacific Cancer Drugs Market Share – by Indications
10.3.4.4.3 India: Asia Pacific Cancer Drugs Market Share – by Distribution Channel
10.4.5.5 South Korea: Asia Pacific Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
10.4.5.5.1 South Korea: Asia Pacific Cancer Drugs Market Share – by Therapy Types
10.4.5.5.2 South Korea: Asia Pacific Cancer Drugs Market Share – by Indications
10.4.5.5.3 South Korea: Asia Pacific Cancer Drugs Market Share – by Distribution Channel
10.5.6.6 Australia: Asia Pacific Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
10.5.6.6.1 Australia: Asia Pacific Cancer Drugs Market Share – by Therapy Types
10.5.6.6.2 Australia: Asia Pacific Cancer Drugs Market Share – by Indications
10.5.6.6.3 Australia: Asia Pacific Cancer Drugs Market Share – by Distribution Channel
10.6.7.7 Rest of APAC: Asia Pacific Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
10.6.7.7.1 Rest of APAC: Asia Pacific Cancer Drugs Market Share – by Therapy Types
10.6.7.7.2 Rest of APAC: Asia Pacific Cancer Drugs Market Share – by Indications
10.6.7.7.3 Rest of APAC: Asia Pacific Cancer Drugs Market Share – by Distribution Channel
11 COMPETITIVE LANDSCAPE
11.1 Heat Map Analysis by Key Players
11.2 Company Positioning & Concentration
12 INDUSTRY LANDSCAPE
12.1 Overview
12.2 New Product Development
12.3 Merger and Acquisition
12.4 Other Strategic Developments
13 COMPANY PROFILES
13.1 F. Hoffmann-La Roche Ltd
13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Products and Services
13.1.4 Financial Overview
13.1.5 SWOT Analysis
13.1.6 Key Developments
13.2 Pfizer Inc
13.2.1 Key Facts
13.2.2 Business Description
13.2.3 Products and Services
13.2.4 Financial Overview
13.2.5 SWOT Analysis
13.2.6 Key Developments
13.3 Novartis AG
13.3.1 Key Facts
13.3.2 Business Description
13.3.3 Products and Services
13.3.4 Financial Overview
13.3.5 SWOT Analysis
13.3.6 Key Developments
13.4 Bristol-Myers Squibb Co
13.4.1 Key Facts
13.4.2 Business Description
13.4.3 Products and Services
13.4.4 Financial Overview
13.4.5 SWOT Analysis
13.4.6 Key Developments
13.5 Johnson & Johnson
13.5.1 Key Facts
13.5.2 Business Description
13.5.3 Products and Services
13.5.4 Financial Overview
13.5.5 SWOT Analysis
13.5.6 Key Developments
13.6 AstraZeneca Plc
13.6.1 Key Facts
13.6.2 Business Description
13.6.3 Products and Services
13.6.4 Financial Overview
13.6.5 SWOT Analysis
13.6.6 Key Developments
13.7 Astellas Pharma Inc
13.7.1 Key Facts
13.7.2 Business Description
13.7.3 Products and Services
13.7.4 Financial Overview
13.7.5 SWOT Analysis
13.7.6 Key Developments
13.8 AbbVie Inc
13.8.1 Key Facts
13.8.2 Business Description
13.8.3 Products and Services
13.8.4 Financial Overview
13.8.5 SWOT Analysis
13.8.6 Key Developments
13.9 Merck KGaA
13.9.1 Key Facts
13.9.2 Business Description
13.9.3 Products and Services
13.9.4 Financial Overview
13.9.5 SWOT Analysis
13.9.6 Key Developments
13.10 Eli Lilly and Co
13.10.1 Key Facts
13.10.2 Business Description
13.10.3 Products and Services
13.10.4 Financial Overview
13.10.5 SWOT Analysis
13.10.6 Key Developments
14. APPENDIX
14.1 About The Insight Partners
1.1 Report Guidance
1.2 Market Segmentation
2. EXECUTIVE SUMMARY
2.1 Key Insights
2.2 Market Attractiveness
3. RESEARCH METHODOLOGY
3.1 Secondary Research
3.2 Primary Research
3.2.1 Hypothesis formulation:
3.2.2 Macroeconomic factor analysis:
3.2.3 Developing base number:
3.2.4 Data Triangulation:
3.2.5 Country-level data:
4. CANCER DRUGS MARKET LANDSCAPE
4.1 Market Overview
4.2 PEST Analysis
4.3 Ecosystem Analysis
4.4 List of Vendors in the Value Chain
5. ASIA PACIFIC CANCER DRUGS MARKET – KEY MARKET DYNAMICS
5.1 Market Drivers
5.2 Market Restraints
5.3 Market Opportunities
5.4 Future Trends
5.5 Impact of Drivers and Restraints:
6. CANCER DRUGS MARKET - ASIA PACIFIC MARKET ANALYSIS
6.1 Asia Pacific Cancer Drugs Market Revenue (US$ Million), 2024 – 2031
6.2 Asia Pacific Cancer Drugs Market Forecast and Analysis
7. ASIA PACIFIC CANCER DRUGS MARKET REVENUE ANALYSIS – BY THERAPY TYPES
7.1 Chemotherapy
7.1.1 Overview
7.1.2 Chemotherapy: Asia Pacific Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
7.2 Targeted Therapy
7.2.1 Overview
7.2.2 Targeted Therapy: Asia Pacific Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
7.3 Immunotherapy
7.3.1 Overview
7.3.2 Immunotherapy: Asia Pacific Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
7.4 Hormonal Therapy
7.4.1 Overview
7.4.2 Hormonal Therapy: Asia Pacific Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
7.5 Other Therapy Types
7.5.1 Overview
7.5.2 Other Therapy Types: Asia Pacific Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
8. ASIA PACIFIC CANCER DRUGS MARKET REVENUE ANALYSIS – BY INDICATIONS
8.1 Blood Cancer
8.1.1 Overview
8.1.2 Blood Cancer: Asia Pacific Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
8.2 Lung Cancer
8.2.1 Overview
8.2.2 Lung Cancer: Asia Pacific Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
8.3 Breast Cancer
8.3.1 Overview
8.3.2 Breast Cancer: Asia Pacific Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
8.4 Colorectal Cancer
8.4.1 Overview
8.4.2 Colorectal Cancer: Asia Pacific Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
8.5 Prostate Cancer
8.5.1 Overview
8.5.2 Prostate Cancer: Asia Pacific Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
8.6 Stomach Cancer
8.6.1 Overview
8.6.2 Stomach Cancer: Asia Pacific Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
8.7 Cervical Cancer
8.7.1 Overview
8.7.2 Cervical Cancer: Asia Pacific Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
8.8 Liver and Intrahepatic Bile Ducts Cancer
8.8.1 Overview
8.8.2 Liver and Intrahepatic Bile Ducts Cancer: Asia Pacific Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
8.9 Thyroid Cancer
8.9.1 Overview
8.9.2 Thyroid Cancer: Asia Pacific Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
8.10 Other Indications
8.10.1 Overview
8.10.2 Other Indications: Asia Pacific Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
9. ASIA PACIFIC CANCER DRUGS MARKET REVENUE ANALYSIS – BY DISTRIBUTION CHANNEL
9.1 Hospital Pharmacies
9.1.1 Overview
9.1.2 Hospital Pharmacies: Asia Pacific Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
9.2 Retail Pharmacies
9.2.1 Overview
9.2.2 Retail Pharmacies: Asia Pacific Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
9.3 Online Stores
9.3.1 Overview
9.3.2 Online Stores: Asia Pacific Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
10. ASIA PACIFIC CANCER DRUGS MARKET – COUNTRY ANALYSIS
10.1 Asia Pacific
10.1.1 Asia Pacific Cancer Drugs Market Revenue and Forecast and Analysis – by Country
10.1.1.1 Asia Pacific Cancer Drugs Market Revenue and Forecast and Analysis – by Country
10.1.2.2 China: Asia Pacific Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
10.1.2.2.1 China: Asia Pacific Cancer Drugs Market Share – by Therapy Types
10.1.2.2.2 China: Asia Pacific Cancer Drugs Market Share – by Indications
10.1.2.2.3 China: Asia Pacific Cancer Drugs Market Share – by Distribution Channel
10.2.3.3 Japan: Asia Pacific Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
10.2.3.3.1 Japan: Asia Pacific Cancer Drugs Market Share – by Therapy Types
10.2.3.3.2 Japan: Asia Pacific Cancer Drugs Market Share – by Indications
10.2.3.3.3 Japan: Asia Pacific Cancer Drugs Market Share – by Distribution Channel
10.3.4.4 India: Asia Pacific Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
10.3.4.4.1 India: Asia Pacific Cancer Drugs Market Share – by Therapy Types
10.3.4.4.2 India: Asia Pacific Cancer Drugs Market Share – by Indications
10.3.4.4.3 India: Asia Pacific Cancer Drugs Market Share – by Distribution Channel
10.4.5.5 South Korea: Asia Pacific Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
10.4.5.5.1 South Korea: Asia Pacific Cancer Drugs Market Share – by Therapy Types
10.4.5.5.2 South Korea: Asia Pacific Cancer Drugs Market Share – by Indications
10.4.5.5.3 South Korea: Asia Pacific Cancer Drugs Market Share – by Distribution Channel
10.5.6.6 Australia: Asia Pacific Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
10.5.6.6.1 Australia: Asia Pacific Cancer Drugs Market Share – by Therapy Types
10.5.6.6.2 Australia: Asia Pacific Cancer Drugs Market Share – by Indications
10.5.6.6.3 Australia: Asia Pacific Cancer Drugs Market Share – by Distribution Channel
10.6.7.7 Rest of APAC: Asia Pacific Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
10.6.7.7.1 Rest of APAC: Asia Pacific Cancer Drugs Market Share – by Therapy Types
10.6.7.7.2 Rest of APAC: Asia Pacific Cancer Drugs Market Share – by Indications
10.6.7.7.3 Rest of APAC: Asia Pacific Cancer Drugs Market Share – by Distribution Channel
11 COMPETITIVE LANDSCAPE
11.1 Heat Map Analysis by Key Players
11.2 Company Positioning & Concentration
12 INDUSTRY LANDSCAPE
12.1 Overview
12.2 New Product Development
12.3 Merger and Acquisition
12.4 Other Strategic Developments
13 COMPANY PROFILES
13.1 F. Hoffmann-La Roche Ltd
13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Products and Services
13.1.4 Financial Overview
13.1.5 SWOT Analysis
13.1.6 Key Developments
13.2 Pfizer Inc
13.2.1 Key Facts
13.2.2 Business Description
13.2.3 Products and Services
13.2.4 Financial Overview
13.2.5 SWOT Analysis
13.2.6 Key Developments
13.3 Novartis AG
13.3.1 Key Facts
13.3.2 Business Description
13.3.3 Products and Services
13.3.4 Financial Overview
13.3.5 SWOT Analysis
13.3.6 Key Developments
13.4 Bristol-Myers Squibb Co
13.4.1 Key Facts
13.4.2 Business Description
13.4.3 Products and Services
13.4.4 Financial Overview
13.4.5 SWOT Analysis
13.4.6 Key Developments
13.5 Johnson & Johnson
13.5.1 Key Facts
13.5.2 Business Description
13.5.3 Products and Services
13.5.4 Financial Overview
13.5.5 SWOT Analysis
13.5.6 Key Developments
13.6 AstraZeneca Plc
13.6.1 Key Facts
13.6.2 Business Description
13.6.3 Products and Services
13.6.4 Financial Overview
13.6.5 SWOT Analysis
13.6.6 Key Developments
13.7 Astellas Pharma Inc
13.7.1 Key Facts
13.7.2 Business Description
13.7.3 Products and Services
13.7.4 Financial Overview
13.7.5 SWOT Analysis
13.7.6 Key Developments
13.8 AbbVie Inc
13.8.1 Key Facts
13.8.2 Business Description
13.8.3 Products and Services
13.8.4 Financial Overview
13.8.5 SWOT Analysis
13.8.6 Key Developments
13.9 Merck KGaA
13.9.1 Key Facts
13.9.2 Business Description
13.9.3 Products and Services
13.9.4 Financial Overview
13.9.5 SWOT Analysis
13.9.6 Key Developments
13.10 Eli Lilly and Co
13.10.1 Key Facts
13.10.2 Business Description
13.10.3 Products and Services
13.10.4 Financial Overview
13.10.5 SWOT Analysis
13.10.6 Key Developments
14. APPENDIX
14.1 About The Insight Partners
LIST OF TABLES
Table 1. Asia Pacific Cancer Drugs Market Segmentation
Table 2. List of Vendors
Table 3. Asia Pacific Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
Table 4. Asia Pacific Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by Therapy Types
Table 5. Asia Pacific Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by Indications
Table 6. Asia Pacific Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by Distribution Channel
Table 7. Asia Pacific Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by Country
Table 8. China: Asia Pacific Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by Therapy Types
Table 9. China: Asia Pacific Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by Indications
Table 10. China: Asia Pacific Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by Distribution Channel
Table 11. Japan: Asia Pacific Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by Therapy Types
Table 12. Japan: Asia Pacific Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by Indications
Table 13. Japan: Asia Pacific Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by Distribution Channel
Table 14. India: Asia Pacific Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by Therapy Types
Table 15. India: Asia Pacific Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by Indications
Table 16. India: Asia Pacific Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by Distribution Channel
Table 17. South Korea: Asia Pacific Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by Therapy Types
Table 18. South Korea: Asia Pacific Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by Indications
Table 19. South Korea: Asia Pacific Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by Distribution Channel
Table 20. Australia: Asia Pacific Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by Therapy Types
Table 21. Australia: Asia Pacific Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by Indications
Table 22. Australia: Asia Pacific Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by Distribution Channel
Table 23. Rest of APAC: Asia Pacific Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by Therapy Types
Table 24. Rest of APAC: Asia Pacific Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by Indications
Table 25. Rest of APAC: Asia Pacific Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by Distribution Channel
Table 26. Heat Map Analysis by Key Players
Table 1. Asia Pacific Cancer Drugs Market Segmentation
Table 2. List of Vendors
Table 3. Asia Pacific Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
Table 4. Asia Pacific Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by Therapy Types
Table 5. Asia Pacific Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by Indications
Table 6. Asia Pacific Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by Distribution Channel
Table 7. Asia Pacific Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by Country
Table 8. China: Asia Pacific Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by Therapy Types
Table 9. China: Asia Pacific Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by Indications
Table 10. China: Asia Pacific Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by Distribution Channel
Table 11. Japan: Asia Pacific Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by Therapy Types
Table 12. Japan: Asia Pacific Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by Indications
Table 13. Japan: Asia Pacific Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by Distribution Channel
Table 14. India: Asia Pacific Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by Therapy Types
Table 15. India: Asia Pacific Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by Indications
Table 16. India: Asia Pacific Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by Distribution Channel
Table 17. South Korea: Asia Pacific Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by Therapy Types
Table 18. South Korea: Asia Pacific Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by Indications
Table 19. South Korea: Asia Pacific Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by Distribution Channel
Table 20. Australia: Asia Pacific Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by Therapy Types
Table 21. Australia: Asia Pacific Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by Indications
Table 22. Australia: Asia Pacific Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by Distribution Channel
Table 23. Rest of APAC: Asia Pacific Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by Therapy Types
Table 24. Rest of APAC: Asia Pacific Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by Indications
Table 25. Rest of APAC: Asia Pacific Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by Distribution Channel
Table 26. Heat Map Analysis by Key Players
LIST OF FIGURES
Figure 1. Asia Pacific Cancer Drugs Market Segmentation – Country
Figure 2. PEST Analysis
Figure 3. Ecosystem: Cancer Drugs Market
Figure 4. Asia Pacific Cancer Drugs Market – Key Market Dynamics
Figure 5. Impact Analysis of Drivers and Restraints
Figure 6. Asia Pacific Cancer Drugs Market Revenue (US$ Million), 2024 – 2031
Figure 7. Asia Pacific Cancer Drugs Market Share (%) – by Therapy Types, 2024 and 2031
Figure 8. Chemotherapy: Asia Pacific Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
Figure 9. Targeted Therapy: Asia Pacific Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
Figure 10. Immunotherapy: Asia Pacific Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
Figure 11. Hormonal Therapy: Asia Pacific Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
Figure 12. Other Therapy Types: Asia Pacific Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
Figure 13. Asia Pacific Cancer Drugs Market Share (%) – by Indications, 2024 and 2031
Figure 14. Blood Cancer: Asia Pacific Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
Figure 15. Lung Cancer: Asia Pacific Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
Figure 16. Breast Cancer: Asia Pacific Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
Figure 17. Colorectal Cancer: Asia Pacific Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
Figure 18. Prostate Cancer: Asia Pacific Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
Figure 19. Stomach Cancer: Asia Pacific Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
Figure 20. Cervical Cancer: Asia Pacific Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
Figure 21. Liver and Intrahepatic Bile Ducts Cancer: Asia Pacific Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
Figure 22. Thyroid Cancer: Asia Pacific Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
Figure 23. Other Indications: Asia Pacific Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
Figure 24. Asia Pacific Cancer Drugs Market Share (%) – by Distribution Channel, 2024 and 2031
Figure 25. Hospital Pharmacies: Asia Pacific Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
Figure 26. Retail Pharmacies: Asia Pacific Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
Figure 27. Online Stores: Asia Pacific Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
Figure 28. Asia Pacific Cancer Drugs Market Breakdown by Key Countries, 2024 and 2031 (%)
Figure 29. China: Asia Pacific Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
Figure 30. Japan: Asia Pacific Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
Figure 31. India: Asia Pacific Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
Figure 32. South Korea: Asia Pacific Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
Figure 33. Australia: Asia Pacific Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
Figure 34. Rest of APAC: Asia Pacific Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
Figure 35. Company Positioning & Concentration
Figure 1. Asia Pacific Cancer Drugs Market Segmentation – Country
Figure 2. PEST Analysis
Figure 3. Ecosystem: Cancer Drugs Market
Figure 4. Asia Pacific Cancer Drugs Market – Key Market Dynamics
Figure 5. Impact Analysis of Drivers and Restraints
Figure 6. Asia Pacific Cancer Drugs Market Revenue (US$ Million), 2024 – 2031
Figure 7. Asia Pacific Cancer Drugs Market Share (%) – by Therapy Types, 2024 and 2031
Figure 8. Chemotherapy: Asia Pacific Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
Figure 9. Targeted Therapy: Asia Pacific Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
Figure 10. Immunotherapy: Asia Pacific Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
Figure 11. Hormonal Therapy: Asia Pacific Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
Figure 12. Other Therapy Types: Asia Pacific Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
Figure 13. Asia Pacific Cancer Drugs Market Share (%) – by Indications, 2024 and 2031
Figure 14. Blood Cancer: Asia Pacific Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
Figure 15. Lung Cancer: Asia Pacific Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
Figure 16. Breast Cancer: Asia Pacific Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
Figure 17. Colorectal Cancer: Asia Pacific Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
Figure 18. Prostate Cancer: Asia Pacific Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
Figure 19. Stomach Cancer: Asia Pacific Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
Figure 20. Cervical Cancer: Asia Pacific Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
Figure 21. Liver and Intrahepatic Bile Ducts Cancer: Asia Pacific Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
Figure 22. Thyroid Cancer: Asia Pacific Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
Figure 23. Other Indications: Asia Pacific Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
Figure 24. Asia Pacific Cancer Drugs Market Share (%) – by Distribution Channel, 2024 and 2031
Figure 25. Hospital Pharmacies: Asia Pacific Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
Figure 26. Retail Pharmacies: Asia Pacific Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
Figure 27. Online Stores: Asia Pacific Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
Figure 28. Asia Pacific Cancer Drugs Market Breakdown by Key Countries, 2024 and 2031 (%)
Figure 29. China: Asia Pacific Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
Figure 30. Japan: Asia Pacific Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
Figure 31. India: Asia Pacific Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
Figure 32. South Korea: Asia Pacific Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
Figure 33. Australia: Asia Pacific Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
Figure 34. Rest of APAC: Asia Pacific Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
Figure 35. Company Positioning & Concentration
